Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing

NDA FilingPositive

AI Analysis

Summary

Compass Pathways announced positive durability data from its second pivotal psilocybin trial for depression, with patients maintaining treatment response for at least six months, supporting the company's plan to complete its NDA filing by year-end.

Clinical Trial Data

Phase

Phase_3

Primary Endpoint

Met

Outcome Details

Patients maintained treatment response for at least six months in second pivotal trial

Importance:7/10

Sentiment:

0.70

psilocybindepressionNDA filingpivotal trialdurability data

Related Companies

$CMPS

Read the original article

Published by Endpoints News on July 7, 2026 3:27 PM

Read Original